全文获取类型
收费全文 | 2072600篇 |
免费 | 154047篇 |
国内免费 | 3913篇 |
专业分类
耳鼻咽喉 | 27397篇 |
儿科学 | 69361篇 |
妇产科学 | 58303篇 |
基础医学 | 305052篇 |
口腔科学 | 58380篇 |
临床医学 | 192045篇 |
内科学 | 400424篇 |
皮肤病学 | 45784篇 |
神经病学 | 166088篇 |
特种医学 | 78103篇 |
外国民族医学 | 554篇 |
外科学 | 299656篇 |
综合类 | 46241篇 |
现状与发展 | 3篇 |
一般理论 | 922篇 |
预防医学 | 169184篇 |
眼科学 | 47186篇 |
药学 | 150944篇 |
44篇 | |
中国医学 | 3795篇 |
肿瘤学 | 111094篇 |
出版年
2018年 | 21937篇 |
2017年 | 16867篇 |
2016年 | 18816篇 |
2015年 | 21514篇 |
2014年 | 29693篇 |
2013年 | 45559篇 |
2012年 | 60999篇 |
2011年 | 65186篇 |
2010年 | 38243篇 |
2009年 | 36411篇 |
2008年 | 61043篇 |
2007年 | 65175篇 |
2006年 | 65134篇 |
2005年 | 63252篇 |
2004年 | 61192篇 |
2003年 | 58806篇 |
2002年 | 56903篇 |
2001年 | 91993篇 |
2000年 | 94158篇 |
1999年 | 79268篇 |
1998年 | 22537篇 |
1997年 | 20467篇 |
1996年 | 20763篇 |
1995年 | 19815篇 |
1994年 | 18432篇 |
1993年 | 17213篇 |
1992年 | 63522篇 |
1991年 | 62372篇 |
1990年 | 61054篇 |
1989年 | 58977篇 |
1988年 | 54141篇 |
1987年 | 53801篇 |
1986年 | 50848篇 |
1985年 | 48548篇 |
1984年 | 36818篇 |
1983年 | 31724篇 |
1982年 | 18980篇 |
1981年 | 17182篇 |
1979年 | 34640篇 |
1978年 | 25322篇 |
1977年 | 21251篇 |
1976年 | 19940篇 |
1975年 | 21259篇 |
1974年 | 25836篇 |
1973年 | 25186篇 |
1972年 | 23652篇 |
1971年 | 22008篇 |
1970年 | 20642篇 |
1969年 | 19364篇 |
1968年 | 18008篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
P. Herent B. Schmauch P. Jehanno O. Dehaene C. Saillard C. Balleyguier J. Arfi-Rouche S. Jégou 《Diagnostic and interventional imaging》2019,100(4):219-225
Purpose
The purpose of this study was to assess the potential of a deep learning model to discriminate between benign and malignant breast lesions using magnetic resonance imaging (MRI) and characterize different histological subtypes of breast lesions.Materials and methods
We developed a deep learning model that simultaneously learns to detect lesions and characterize them. We created a lesion-characterization model based on a single two-dimensional T1-weighted fat suppressed MR image obtained after intravenous administration of a gadolinium chelate selected by radiologists. The data included 335 MR images from 335 patients, representing 17 different histological subtypes of breast lesions grouped into four categories (mammary gland, benign lesions, invasive ductal carcinoma and other malignant lesions). Algorithm performance was evaluated on an independent test set of 168 MR images using weighted sums of the area under the curve (AUC) scores.Results
We obtained a cross-validation score of 0.817 weighted average receiver operating characteristic (ROC)-AUC on the training set computed as the mean of three-shuffle three-fold cross-validation. Our model reached a weighted mean AUC of 0.816 on the independent challenge test set.Conclusion
This study shows good performance of a supervised-attention model with deep learning for breast MRI. This method should be validated on a larger and independent cohort. 相似文献82.
83.
Annette E Hay Nicole Mittmann Michael Crump Matthew C Cheung Jessica Sleeth Judy Needham Mike Broekhoven Marina Djurfeldt Lois E Shepherd Ralph M Meyer Bingshu E Chen Joseph L Pater 《Current oncology (Toronto, Ont.)》2021,28(2):1153
In a prospective study, we sought to determine acceptability of linkage of administrative and clinical trial data among Canadian patients and Research Ethics Boards (REBs). The goal is to develop a more harmonized approach to data, with potential to improve clinical trial conduct through enhanced data quality collected at reduced cost and inconvenience for patients. On completion of the original LY.12 randomized clinical trial in lymphoma (), participants were invited to enrol in the Long-term Innovative Follow-up Extension (LIFE) component. Those consenting to do so provided comprehensive identifying information to facilitate linkage with their administrative data. We prospectively designed a global assessment of this innovative approach to clinical trial follow-up including rates of REB approval and patient consent. The pre-specified benchmark for patient acceptability was 80%. Of 16 REBs who reviewed the research protocol, 14 (89%) provided approval; two in Quebec declined due to small patient numbers. Of 140 patients invited to participate, 115 (82%, 95% CI 76 to 88%) from across 9 Canadian provinces provided consent and their full name, date of birth, health insurance number and postal code to facilitate linkage with their administrative data for long-term follow-up. Linkage of clinical trial and administrative data is feasible and acceptable. Further collaborative work including many stakeholders is required to develop an optimized secure approach to research. A more coordinated national approach to health data could facilitate more rapid testing and identification of new effective treatments across multiple jurisdictions and diseases from diabetes to COVID-19. NCT00078949相似文献
84.
The present study enumerates the attenuating effects of curcumin and α-tocopherol against propoxur induced oxidative DNA damage in human peripheral blood mononuclear cells (PBMC). Cultured cells were isolated from peripheral blood of healthy volunteers, and were exposed to varying concentrations of propoxur (0–21?μg/ml) for 6, 12, and 24?h, and in combination with curcumin (9.2?μg/ml) or α-tocopherol (4.3?μg/ml) or both. Cytotoxic effect of propoxur was examined by MTT assay. The role of oxidative stress beneath the cytotoxicity of propoxur was evaluated by the measurement of reduced glutathione (GSH), malondialdehyde (MDA) and 8-hydroxy-2′-deoxyguanosine (8-OH-dG) levels in cell lysate. A concentration-dependent cell death, depletion of GSH, an increase in the level of both MDA and 8-OH-dG were observed. Co-treatment with curcumin or α-tocopherol significantly attenuates depleted GSH, decrease in MDA and 8-OH-dG levels in propoxur exposed cells (p?0.05). The results of the present study provide experimental evidence of involvement of oxidative stress in propoxur-mediated genotoxicity in human PBMC and highlight the antioxidant role of curcumin and α-tocopherol following propoxur exposure. 相似文献
85.
86.
87.
88.
89.
90.
S. A. Luzhnova A. G. Tyrkov N. M. Gabitova E. A. Yurtaeva 《Pharmaceutical Chemistry Journal》2018,52(6):506-509